Objective: Studies show that adherence to osteoporosis treatment and prevention is low, which could interfere with therapeutic response. The aim of this study was to evaluate the ability of women to follow a treatment for osteoporosis with different anti-reabsorptives in relation to the prescribed regimen, dose, indications, and mode of ingestion. Methods: A cross-sectional study that included postmenopausal women all undergoing medicated treatment because of densitometric diagnosis of osteopenia or osteoporosis was carried out by means of the MedTake questionnaire. A total of 227 women at a menopause clinic were studied. The following were evaluated: sociodemographic characteristics, other illnesses, use of concomitant medication, use of medication for osteoporosis, length of use, and ability to follow the treatment in relation to the prescribed regimen, dose, indication, and mode of ingestion. Results: The ability to follow the treatment as evaluated by the MedTake was below 80% for most of the women. No significant difference was found between the daily or weekly bisphosphonate users and those taking raloxifene. The factors associated with inadequate treatment were the following: being 70 years or older (odds ratio [OR], 5.62; 95% CI, 1.23-25.64), being illiterate (OR, 10.14; 95% CI, 2.14-48.12), use of other medications (OR, 0.33; 95% CI, 15-0.76), and shorter length of use of medication for osteoporosis (OR, 5.67; 95% CI, 2.27-14.16). Conclusion: The ability to follow a treatment involving different anti-reabsorptive medications for osteoporosis is high relative to mode of ingestion, coingestion, and indication and low in relation to knowledge of the correct dose. Low ability is associated with advanced age, being illiterate, not using other medications, and shorter treatment time. © 2011 by The North American Menopause Society.185531536Weycker, D., Macarios, D., Edelsberg, J., Oster, G., Compliance with drug therapy for postmenopausal osteoporosis (2006) Osteoporosis International, 17 (11), pp. 1645-1652. , DOI 10.1007/s00198-006-0179-xAdherence to long term therapies (2003) Evidence for Action, , World Health Organization, Geneva: World Health OrganizationDelmas, P.D., Vrijens, B., Eastell, R., Roux, C., Pols, H.A.P., Ringe, J.D., Grauer, A., Watts, N.B., Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis (2007) Journal of Clinical Endocrinology and Metabolism, 92 (4), pp. 1296-1304. , http://jcem.endojournals.org/cgi/reprint/92/4/1296, DOI 10.1210/jc.2006-1526Raehl, C.L., Bond, C.A., Woods, T., Patry, R.A., Sleeper, R.B., Individualized drug use assessment in the elderly (2002) Pharmacotherapy, 22 (10), pp. 1239-1248Carr, A.J., Thompson, P.W., Cooper, C., Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: A cross-sectional survey (2006) Osteoporosis International, 17 (11), pp. 1638-1644. , DOI 10.1007/s00198-006-0166-2Cramer, J.A., Gold, D.T., Silverman, S.L., Lewiecki, E.M., A systematic review of persistence and compliance with bisphosphonates for osteoporosis (2007) Osteoporosis International, 18 (8), pp. 1023-1031. , DOI 10.1007/s00198-006-0322-8MacLaughlin, E.J., Raehl, C.L., Treadway, A.K., Sterling, T.L., Zoller, D.P., Bond, C.A., Assessing medication adherence in the elderly: Which tools to use in clinical practice? (2005) Drugs and Aging, 22 (3), pp. 231-255. , DOI 10.2165/00002512-200522030-00005McCombs, J.S., Thiebaud, P., McLaughlin-Miley, C., Shi, J., Compliance with drug therapies for the treatment and prevention of osteoporosis (2004) Maturitas, 48 (3), pp. 271-287. , DOI 10.1016/j.maturitas.2004.02.005, PII S0378512204000957Papaioannou, A., Ioannidis, G., Adachi, J.D., Sebaldt, R.J., Ferko, N., Puglia, M., Brown, J., Goldsmith, C.H., Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database (2003) Osteoporosis International, 14 (10), pp. 808-813. , DOI 10.1007/s00198-003-1431-2Cochran, W.G., (1963) Técnicas de Amostragem, , 92nd ed. Portugal: Editora Fundo de CulturaVytrisalova, M., Blazkova, S., Palicka, V., Self-reported compliance with osteoporosis medication-qualitative aspects and correlates (2008) Maturitas, 60, pp. 223-229Huybrechts, K.F., Ishak, K.J., Caro, J.J., Assessment of compliance with osteoporosis treatment and its consequences in a managed care population (2006) Bone, 38 (6), pp. 922-928. , DOI 10.1016/j.bone.2005.10.022, PII S8756328205004436Lee, S., Glendenning, P., Inderjeeth, C.A., Efficacy, side effects and route of administration are more important than frequency of dosing of antiosteoporosis treatments in determining patient adherence: A critical review of published articles from 1970 to 2009 [e-pub] (2010) Osteoporos IntSimon, J.A., Lewiecki, E.M., Smith, M.E., Petruschke, R.A., Wang, L., Palmisano, J.J., Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study (2002) Clinical Therapeutics, 24 (11), pp. 1871-1886. , DOI 10.1016/S0149-2918(02)80085-6Solomon, D.H., Avorn, J., Katz, J.N., Finkelstein, J.S., Arnold, M., Polinski, J.M., Brookhart, M.A., Compliance with osteoporosis medications (2005) Archives of Internal Medicine, 165 (20), pp. 2414-2419. , http://archinte.ama-assn.org/cgi/reprint/165/20/2414, DOI 10.1001/archinte.165.20.2414Park, D.C., Morrell, R.W., Frieske, D., Medication adherence behaviors in older adults: Effects of external cognitive supports (1992) Psychol Aging, 7, pp. 252-256Sharkness, C.M., Snow, D.A., The patient's view of hypertension and compliance (1992) American Journal of Preventive Medicine, 8 (3), pp. 141-146